ODYSSEY OUTCOMES Trial: A Plain-English Overview of What It Established

At a glance

Detail	Value
Full title	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Registry	NCT01663402
N	18,924
Population	Adults 1 to 12 months post-ACS, LDL ≥70 mg/dL on maximally tolerated statin
Intervention	Alirocumab 75 mg or 150 mg SC every 2 weeks
Comparator	Matching placebo injections every 2 weeks
Duration	Median follow-up 2.8 years
Primary endpoint	Composite MACE: coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization
Key result	HR 0.85 (95% CI 0.78, 0.93; P <0.001), a 15% relative risk reduction
Sponsor	Sanofi / Regeneron
Published	2018, New England Journal of Medicine

The Question Behind the Trial

By the mid-2010s, doctors already knew that lowering LDL cholesterol with statins reduced heart attacks and strokes. But a sizable group of patients still had events despite taking the strongest available statin doses. PCSK9 inhibitors, a new class of injectable drugs, could slash LDL by an additional 50 to 60% on top of statins. The open question was whether that extra LDL lowering would translate into fewer heart attacks, strokes, and deaths, or whether it would simply move a lab number without clinical payoff.

The FOURIER trial, published in 2017, had already demonstrated that evolocumab (a different PCSK9 inhibitor) reduced cardiovascular events. ODYSSEY OUTCOMES aimed to answer the same type of question for alirocumab, but in a higher-risk population: patients who had recently suffered an acute coronary syndrome (ACS), meaning a heart attack or unstable angina severe enough to require hospitalization.

Who Was Enrolled

Patients had to meet all of these criteria:

• Hospitalized for ACS (MI or unstable angina) within the previous 1 to 12 months
• LDL cholesterol ≥70 mg/dL, non-HDL cholesterol ≥100 mg/dL, or apolipoprotein B ≥80 mg/dL, despite at least 2 weeks of high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg)
• Age ≥40 years

Key exclusion criteria included uncontrolled hypertension, severe renal impairment (eGFR <30), active liver disease, and a history of hemorrhagic stroke. Patients on background lipid-lowering therapy other than statins (e.g., ezetimibe) were allowed, as long as it was stable. About 89% of randomized patients were on high-intensity statin therapy at baseline. The median baseline LDL was 87 mg/dL, already relatively low thanks to the statin run-in.

Geographically, the trial enrolled patients across 57 countries and 1,315 sites, making it one of the largest cardiovascular outcome trials ever conducted for a lipid-lowering agent.

What Patients Received

Participants were randomized 1:1 to alirocumab or placebo, both administered as subcutaneous injections every two weeks. The trial used a blinded dose-adjustment protocol that was unusual and worth understanding:

• Starting dose: 75 mg every 2 weeks
• Uptitration: If LDL remained ≥50 mg/dL at month 2, the dose was increased to 150 mg every 2 weeks
• Downtitration: If LDL dropped below 15 mg/dL on two consecutive measurements, patients were switched to placebo (while remaining officially in the alirocumab arm for analysis) to avoid sustained very-low LDL levels

This adaptive dosing strategy was a deliberate design choice. The investigators wanted to target an LDL range of 25 to 50 mg/dL rather than simply prescribing the maximum dose to everyone. By month 4, roughly 55% of alirocumab patients remained on 75 mg, about 37% had been uptitrated to 150 mg, and approximately 8% were on blinded placebo due to very low LDL.

What Was Measured

The primary endpoint was a four-component composite of major adverse cardiovascular events (MACE):

1. Death from coronary heart disease
2. Nonfatal myocardial infarction
3. Fatal or nonfatal ischemic stroke
4. Unstable angina requiring hospitalization

This is a standard, guideline-endorsed composite for cardiovascular outcome trials, though the inclusion of hospitalization for unstable angina (which is more subjective than MI or stroke) has been debated in some academic circles.

Key secondary endpoints (tested in a hierarchical, pre-specified order to control for multiple comparisons) included:

• Any coronary heart disease event
• Any cardiovascular event
• A composite of all-cause death, nonfatal MI, and nonfatal ischemic stroke
• All-cause death alone

What the Trial Found

Primary Endpoint

Over a median follow-up of 2.8 years, the primary MACE endpoint occurred in 9.5% of the alirocumab group versus 11.1% of the placebo group. That translates to:

• Hazard ratio: 0.85 (95% CI 0.78, 0.93)
• P value: <0.001
• Absolute risk reduction: 1.6 percentage points
• Number needed to treat (NNT): approximately 63 over 2.8 years

The Kaplan-Meier curves began separating within the first year and continued to diverge through the end of the study period, suggesting a benefit that accumulated with longer treatment duration.

Individual Components

The composite was driven primarily by reductions in nonfatal MI and ischemic stroke. CHD death alone did not reach statistical significance.

All-Cause Mortality

All-cause death was a pre-specified secondary endpoint. In the overall population, the numerical difference favored alirocumab (3.5% vs. 4.1%, HR 0.85, 95% CI 0.73, 0.98). However, because of the hierarchical testing procedure, this result did not meet the pre-specified threshold for formal statistical significance. The preceding endpoint in the testing sequence (composite of all-cause death, nonfatal MI, and nonfatal ischemic stroke) was significant, but the protocol required the all-cause mortality comparison to clear a specific alpha threshold that it narrowly missed.

This is a nuanced but important point. The mortality signal was suggestive, not confirmed, and should be interpreted as hypothesis-generating rather than definitive. The investigators later published a post hoc analysis focusing on patients with baseline LDL ≥100 mg/dL, which showed a more pronounced mortality benefit in that subgroup (HR 0.71, 95% CI 0.56, 0.90). While intriguing, post hoc subgroup analyses carry lower evidentiary weight than pre-specified primary analyses.

LDL Reduction

At month 4, LDL cholesterol in the alirocumab group averaged about 38 mg/dL compared to 93 mg/dL in the placebo group, a relative reduction of roughly 63%. These numbers shifted over time as patients were dose-adjusted and some were switched to blinded placebo.

Safety Profile

Injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% on placebo. There were no significant differences in rates of:

• New-onset diabetes
• Neurocognitive adverse events
• Hepatic events
• Myalgia or rhabdomyolysis

The neurocognitive finding deserves emphasis. Because PCSK9 inhibitors push LDL to levels humans rarely sustain naturally (below 25 mg/dL in some patients), there were theoretical concerns about brain cholesterol metabolism. The ODYSSEY OUTCOMES data, combined with the dedicated EBBINGHAUS neurocognitive sub-study of evolocumab, provided reassurance that very low LDL did not impair cognitive function over these timeframes.

Limitations the Authors Acknowledged

Several limitations were discussed in the original publication and subsequent editorials:

Trial duration. The median 2.8-year follow-up may not capture longer-term benefits or risks. Cardiovascular prevention is a decades-long endeavor, and whether PCSK9 inhibitors sustain their benefit (or reveal delayed adverse effects) beyond 3 to 4 years remains uncertain.

Adaptive dosing complicates interpretation. The blinded dose-switching protocol, while clinically sensible, makes it harder to define a single "dose-response" relationship. About 8% of the alirocumab arm was actually receiving placebo by the end of the trial, diluting the treatment effect in intention-to-treat analysis.

Population specificity. ODYSSEY OUTCOMES enrolled post-ACS patients only. Generalizing these results to primary prevention or to patients with stable coronary disease requires caution, though the broader LDL-lowering evidence base supports a consistent relationship between LDL reduction and cardiovascular risk across populations.

Subgroup-driven mortality signal. The suggestive mortality benefit was concentrated in patients with higher baseline LDL. This is biologically plausible (more room for LDL lowering means more potential benefit), but it was not a pre-specified primary analysis.

Cost and access. When the trial was published, alirocumab's list price exceeded $14,000 per year in the United States. FDA labeling for Praluent was updated to include the cardiovascular risk reduction indication, but insurance coverage remained inconsistent. Since then, substantial price reductions have improved access, though cost-effectiveness debates continue.

What Changed in Clinical Practice

Before ODYSSEY OUTCOMES, the 2017 ACC/AHA cholesterol guideline update already positioned PCSK9 inhibitors as an option for very-high-risk patients not at LDL goal on maximally tolerated statins plus ezetimibe. The trial strengthened that recommendation in several ways:

1. It confirmed MACE reduction in a second PCSK9 inhibitor (alirocumab), making the benefit a class effect rather than molecule-specific.
2. It provided data in the highest-risk subgroup (recent ACS), where the absolute benefit is greatest.
3. The adaptive dosing model influenced real-world prescribing. Many clinicians now start at the lower dose and titrate based on LDL response, mirroring the trial protocol.
4. The suggestive mortality data, combined with meta-analyses of statin and non-statin LDL-lowering trials, reinforced the principle that the magnitude of cardiovascular benefit correlates with the magnitude of LDL reduction, regardless of mechanism.

Today, PCSK9 inhibitors are standard recommendations in guidelines from the ACC/AHA, ESC/EAS, and other professional societies for patients with atherosclerotic cardiovascular disease who remain above LDL targets despite statins and ezetimibe.

Bottom Line for Patients

If you had a heart attack or severe episode of unstable angina in the past year and your LDL cholesterol is still above 70 mg/dL despite taking a high-dose statin, alirocumab (given as a shot every two weeks) reduced the chance of another major cardiovascular event by about 15% over roughly three years. The absolute risk reduction was modest (about 1.6 percentage points), but for patients at very high risk, even modest absolute reductions can be clinically meaningful. The drug was well-tolerated in this trial, with no clear signal of serious harm including at very low LDL levels.

Frequently asked questions

›What does ODYSSEY OUTCOMES stand for?

ODYSSEY was the name of the alirocumab clinical development program. OUTCOMES specifically refers to the cardiovascular outcomes trial. The full trial name is "Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab."

›How is alirocumab different from evolocumab?

Both are PCSK9 inhibitors that work by blocking the same protein to lower LDL cholesterol. Alirocumab (brand name Praluent) was studied in ODYSSEY OUTCOMES; evolocumab (brand name Repatha) was studied in the FOURIER trial. Both demonstrated cardiovascular event reduction. They differ in dosing options, injection devices, and some pharmacokinetic properties, but head-to-head trials comparing the two drugs have not been conducted.

›Did ODYSSEY OUTCOMES prove that alirocumab reduces death?

Not definitively. All-cause death was numerically lower in the alirocumab group (3.5% vs. 4.1%), but this result did not meet the pre-specified threshold for formal statistical significance due to the hierarchical testing procedure. A post hoc subgroup analysis in patients with baseline LDL ≥100 mg/dL showed a stronger mortality signal, but post hoc analyses are considered hypothesis-generating.

›Who qualifies for alirocumab based on this trial?

The trial enrolled adults over 40 who had an acute coronary syndrome in the preceding 1 to 12 months and whose LDL remained ≥70 mg/dL on high-intensity statin therapy. In practice, guidelines recommend considering PCSK9 inhibitors for patients with atherosclerotic cardiovascular disease who remain above their LDL target despite maximum tolerated statin plus ezetimibe.

›How much does alirocumab cost?

When first approved, the annual list price exceeded $14,000 in the US. Sanofi and Regeneron reduced the price substantially in subsequent years. Actual out-of-pocket cost varies widely based on insurance coverage, manufacturer copay assistance programs, and prior authorization requirements. Check the FDA-approved Praluent label and your insurer's formulary for current pricing.

›Is it safe to lower LDL below 25 mg/dL?

In ODYSSEY OUTCOMES, patients whose LDL dropped below 15 mg/dL were switched to blinded placebo as a precaution. No increase in neurocognitive events, liver problems, or other serious adverse effects was observed at very low LDL levels during the trial's follow-up period. Longer-term safety data at extremely low LDL levels are still accumulating.

›Can I take alirocumab instead of a statin?

ODYSSEY OUTCOMES tested alirocumab on top of a statin, not as a replacement. Current guidelines recommend maximizing statin therapy first, then adding ezetimibe if needed, and considering a PCSK9 inhibitor as a third step. There is limited outcomes data supporting PCSK9 inhibitor monotherapy, though some patients who are truly statin-intolerant do receive them.

›How long do you need to take alirocumab to see benefit?

In the trial, the Kaplan-Meier curves for MACE began separating within the first year. The benefit increased over time through the 2.8-year median follow-up. Clinical guidelines generally recommend continued therapy as long as the patient remains at elevated cardiovascular risk, which for most post-ACS patients is indefinitely.

›What was the number needed to treat in ODYSSEY OUTCOMES?

Approximately 63 patients needed to be treated for 2.8 years to prevent one primary MACE event. In the subgroup with baseline LDL ≥100 mg/dL, the NNT was lower (more favorable), consistent with a greater absolute benefit in patients starting further from their LDL goal.

›Did ODYSSEY OUTCOMES change treatment guidelines?

Yes. The trial strengthened guideline recommendations from the ACC/AHA (2018 cholesterol guideline) and ESC/EAS (2019 dyslipidemia guideline) supporting PCSK9 inhibitor use in very-high-risk patients with atherosclerotic cardiovascular disease not at LDL target on maximally tolerated statin plus ezetimibe.

References

1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. PubMed
3. Praluent (alirocumab) prescribing information. US Food and Drug Administration. FDA Label
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC cholesterol clinical practice guideline. Circulation. 2019;139(25):e1082-e1143. PubMed
5. Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387-396. PubMed
6. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis. Lancet. 2015;385(9976):1397-1405. PubMed